FLIPI-2Follicular Lymphoma Prognostic Index
Demographics & Serology
Tumor Burden & Staging
Awaiting Clinical Inputs
The FLIPI-2 is the updated clinical standard for risk-stratifying patients with follicular lymphoma.
Risk Tiers
- 0 Points: Low Risk
- 1-2 Points: Intermediate
- >=3 Points: High Risk
Guidelines & Evidence
Verified
Last Review: 2026
When to Use
When to Use
Initial prognostic assessment of patients with newly diagnosed, untreated follicular lymphoma (FL)
Risk stratification in the immunochemotherapy era — FLIPI2 was specifically developed and validated in rituximab-treated populations
To guide rational selection of patients who may benefit from more intensified treatment regimens
To identify low-risk patients within the FLIPI low-risk group who may still have meaningfully different PFS outcomes
Applicable across patients receiving first-line R-chemotherapy (R-CHOP, R-CVP, fludarabine-based regimens)
Can be used alongside PRIMA-PI for patients receiving first-line immunochemotherapy; the two indices are complementary
Patient Population
Derived from 832 patients with complete data in the prospective international F2 study (Federico et al., 2009), registered across 69 European and American institutions between January 2003 and May 2005. Validated externally in an independent Italian cohort of 231 patients (Federico et al., 2009) and in a further independent series of 280 patients by Arcaini et al. (2010). Covers FL grade 1–3a; not validated for grade 3b or concurrent transformation to DLBCL.
Special Population: Elderly Patients (≥ 60 years)
Because age ≥ 60 years is itself a FLIPI2 risk factor, all elderly patients (≥ 60) are automatically excluded from the low-risk FLIPI2 group and can only be classified as intermediate or high risk. Wang et al. (Heliyon 2025) developed the Age-adjusted FLIPI2 (A-FLIPI2), which re-sets the age threshold to ≥ 70 years, restoring three-tier stratification in patients aged ≥ 60. A-FLIPI2 demonstrated superior AUC for death prediction (0.793 vs 0.704 for FLIPI2) and disease progression (0.678 vs 0.620) in 128 elderly FL patients, with external validation in a further 67 cases.
When Not to Rely on FLIPI2 Alone
FL grade 3b — behaves more like aggressive lymphoma; use DLBCL-specific indices (IPI)
Concurrent transformation to diffuse large B-cell lymphoma at diagnosis — not captured by FLIPI2
Watch-and-wait policy — PFS events are not comparable to treated patients; FLIPI2 was built on treated populations only
Do not use FLIPI2 to defer treatment in a high-risk patient if clinical judgement indicates need for immediate therapy
Elderly patients (≥ 60): consider A-FLIPI2 for more meaningful three-tier stratification in this cohort
Last Comprehensive Review: 2026